Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab - Koren, M J; Lundqvist, P; Bolognese, MMENDEL-2 Investigators (J Am Coll Cardiol, 2014)
et al.